Physiological and pathophysiological actions of insulin in the liver
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
The liver plays an important role in the control of glucose homeostasis. When insulin levels are low, such as in the fasting state, gluconeogenesis and glycogenolysis are stimulated to maintain the blood glucose levels. Conversely, in the presence of increased insulin levels, such as after a meal, synthesis of glycogen and lipid occurs to maintain the blood glucose levels within normal range. Insulin receptor signaling regulates glycogenesis, gluconeogenesis and lipogenesis through downstream pathways such as the insulin receptor substrate (IRS)-phosphoinositide 3 (PI3) kinase-Akt pathway. IRS-1 and IRS-2 are abundantly expressed in the liver and are thought to be responsible for transmitting the insulin signal from the insulin receptor to the intracellular effectors involved in the regulation of glucose and lipid homeostasis. Impaired insulin receptor signaling can cause hepatic insulin resistance and lead to type 2 diabetes. In the present study, we focus on a concept called "selective insulin resistance," which has received increasing attention recently: the frequent coexistence of hyperglycemia and hepatic steatosis in people with type 2 diabetes and obesity suggests that it is possible for the insulin signaling regulating gluconeogenesis to be impaired even while that regulating lipogenesis is preserved, suggestive of selective insulin resistance. In this review, we review the progress in research on the insulin actions and insulin signaling in the liver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The concept of hepatic zonation of insulin signaling components can also help explain the paradoxical coexistence of increased hepatic glucose output and increased hepatic lipogenesis in MASLD [15,20].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 1×
“Activation of NFκB promotes further inflammatory gene expressions [83, 84] and inhibits insulin signaling through serine phosphorylation of IRS-1 or other insulin signaling molecules, leading to hepatic insulin resistance [85, 86].”
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326 · cited 1×
“Although several isoforms of IRS have been identified, including IRS-1, -2, -3, -4, -5, and -6 [9, 10, 16-19], IRS-1 and IRS-2 constitute the main IRS iso‐ forms expressed in the liver [20-22]; IRS-6 is almost not detectable at all in the liver [19].”
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244 · cited 1×
“Glycogen synthase kinase-3 (GSK3) β is reported to play an important role in the regulation of insulin-induced glycogen synthesis [36, 37].”
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760 · cited 2×
“Insulin receptor signaling through pathways downstream of the insulin receptor, such as the insulin receptor substrate (IRS)-phosphoinositide 3 (PI3) kinase-Akt pathway, is known to regulate glycogenesis, gluconeogenesis, and lipogenesis [7].”
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Cited by
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“Insulin receptor substrate 1 (IRS1) and IRS2 among IRS1–6 are the main adaptor proteins in the liver, activating phosphatidylinositol-3 kinase (PI3K) [9,11,15,19].”
InfluentialAccacha, S. D., Barillas, J., Srivastava, A., Ross, F., Drewes, W., Gulkarov, S., Leon, J. D., & Reiss, A. B. (2025) · Metabolites · doi:10.3390/metabo15050287 · Cited by 39
“In the liver, the main mediators of insulin signaling are insulin receptor substrate 1 (IRS1) and insulin receptor substrate 2 (IRS2) [61].”
Quercetin as an Anti-Diabetic Agent in Rodents—Is It Worth Testing in Humans?
Szkudelski, T., Szkudelska, K., & Łangowska, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157391 · Cited by 4
“However, quercetin therapy restored PEPCK activity to normal levels [32,99].”
InfluentialYang, Q., Xu, Y., Zhang, J., Xiao, N., Lu, H., Chen, B., Yang, B., Xie, Z., & Li, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1794782 · Cited by 6
“This results in hypergluconeogenesis and fasting hyperglycemia (85, 86).”
Nhau, P. T., Gamede, M. W., Khathi, A., & Sibiya, N. H. (2025) · Pathophysiology · doi:10.3390/pathophysiology32030039 · Cited by 3
Minchenko, О. H., Viletska, Y. M., Abramchuk, A. I., Sliusar, M. Y., Halkin, O. V., Khikhlo, Y. P., Danilovskyi, S. V., Luzina, O. Y., & Minchenko, D. O. (2025) · Endocrine Regulations · doi:10.2478/enr-2025-0020 · Cited by 2
“Phosphorylated IRS2 plays an important role not only in the glucose homeostasis, but also in the development, growth, and tumorigenesis (Copps and White 2012; Porter et al. 2013; Manohar et al. 2020; Kubota et al. 2025).”
Zhang, Z., Xu, X., Chen, F., Liu, Q., Li, Z., Zheng, X., & Zhao, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031096 · Cited by 2
Tura, A., Sonntag, S. R., von Bubnoff, N. C. C., Spielmann, M., & Grisanti, S. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.15.10
“22,23 Insulin resistance is therefore associated with a longer period of postprandial hyperglycemia, 23 which may remain undetected for many years due to the appearance of the fasting blood glucose concentration at physiological levels.”
Zhang, Y., Sun, Y., Liu, J., Dong, J., Cao, C., Qi, M., Li, S., Zhang, H., Gao, Z., & Song, H. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115842
NASEER, M., Tariq, M., Waheed, N., Khan, B., Kalhoro, D. M., Ali, S., Khan, H., Hussain, A., Kakar, N. U., Shah, A. A., et al. (2026) · Molecular Syndromology · doi:10.1159/000553060
Chen, X., Ma, K., Shi, Y., Li, Y., Ji, Y., & Liu, Y. (2026) · Microorganisms · doi:10.3390/microorganisms14061356
“The liver serves as a primary site for glucose metabolism and insulin action [24].”
Haleem, E. N. A. A., & Yousef, B. A. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.71005
Wang, S., Feng, Y.-S., Zhang, Y.-K., & Wang, S.-X. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122166
Teofilović, B. D., Trkulja, J., Grujić-Letić, N. N., Gligorić, E. I., Baletic, D., Tomić, L., Mesarović, A., & Rašković, A. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2727202
“Hepatic glycogen synthesis is also reduced, manifesting as diminished postprandial and post-absorptive glucose storage 20 .”
Cheng, Y.-Q., Wei, M., Yang, L., Zhuang, Y., & Lu, Q.-B. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102787
“As the first organ to which the pancreatic insulin acts, the liver controls glucose balance by modulating gluconeogenesis, glycogenesis and glycogenol-ysis [8].”
Metabolic effects of a GLP-1 analog combined with aerobic training in ovariectomized rats
Selau, B., Bastos, L. M., Normann, R. S., Cubas, G. K., Herrmann, R. D. O. C. D. C., de Barros, L. D. A. D. O., de Amaral, M., Trapp, M., Kucharski, L. C., Vogt, É. L., et al. (2026) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2026.112917
Syringin inhibits insulin resistance through the PI3K/AKT pathway
Wang, H., Han, J., Yun, L., & Wang, X. (2026) · Acta Pharmaceutica · doi:10.2478/acph-2026-0024
“It has been observed that the presence of IR in HepG2 cells primarily leads to impaired glycogen synthesis, an inability to control glucose production, and is closely associated with the onset of hyperglycemia (11).”
Insulin resistance & antidiabetic medications: Diverse mechanisms and mitigation strategies
Ray, S. D., Rottersman, S., He, L. (. L., Leo, M. E. D., Siu, J. (. T., & Gray, J. P. (2026) · Side effects of drugs annual · doi:10.1016/bs.seda.2026.09.008
Metadata
- Authors
- Kubota, N., Kubota, T., & Kadowaki, T.
- Affiliations
- Kumamoto University (JP)
- The Institute of Medical Science, Asahi Life Foundation (JP)
- Toranomon Hospital (JP)
- Corresponding author
- Kubota, Naoto
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2025
- Volume
- 72
- Issue
- 2
- Pages
- 149-159
- ISSN
- 0918-8959 (ISSN-L)
- 1348-4540
- PMC
- PMC11850106
- OpenAlex
- W4402120026
- Cited by
- 19
- References
- 115
- Citations by year
- 2026: 12 · 2025: 7
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Endocrine Journal (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (24K02500)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin signaling, liver, glucose homeostasis, gluconeogenesis, glycogen synthesis, lipogenesis, hepatic insulin resistance, insulin receptor substrate, PI3K/Akt signaling, type 2 diabetes, hepatic steatosis, obesity
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Gluconeogenesis, Humans, Insulin, Insulin Resistance, Liver, Receptor, Insulin, Signal Transduction, Lipogenesis, Insulin Receptor Substrate Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.